Analyst Research

Report Title Price
Provider: Reuters Investment Profile
Provider: Sadif Analytics Prime
Provider: Wright Reports
Provider: GlobalData

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Aspen Pharmacare Holdings Ltd Updates On Acquisition From MSD Of An API Manufacturing Business And Portfolio Of Products

Tuesday, 1 Oct 2013 03:00am EDT 

Aspen Pharmacare Holdings Ltd announced that with reference to the announcement made on June 27, 2013, wherein it was confirmed that the Aspen Group (Aspen) had: signed an agreement with MSD (known as Merck in the United States and Canada) for the acquisition of an active pharmaceutical ingredient (API) manufacturing business which manufactures for MSD and the market generally and which is located in the Netherlands with a satellite facility and sales office in the US (the API Business); and reached an agreement on an option to acquire a portfolio of 11 branded finished dose form molecules (the Products ) from MSD, covering a diverse range of therapeutic areas and including products that use APIs manufactured by the API Business (collectively the Transactions). The Company now announced that the parties have agreed that all the contractual conditions precedent necessary to implement the acquisition of the API Business have now been met. The API Business has been transferred to Aspen with effect from October 01, 2013. As confirmed in the announcement released on June 27, 2013, the expected effective date of the Products acquisition, through the exercise of the option, is December 31, 2013 and a further announcement will be made once this aspect of the Transactions has been completed. 

Company Quote

76.0 +0.21%
7:35am EDT